A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum | Zendy

Animesh Saha | Zendy; Sajal K. Ghosh | Zendy; Chhaya Roy | Zendy; Makhan Saha | Zendy; Krishnangshu Bhanja Choudhury | Zendy; Koushik Chatterjee | Zendy

Open Access

A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum

Author(s) -

Animesh Saha,

Sajal K. Ghosh,

Chhaya Roy,

Makhan Saha,

Krishnangshu Bhanja Choudhury,

Koushik Chatterjee

Publication year - 2015

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.150341

Subject(s) - medicine , oxaliplatin , capecitabine , fluorouracil , folfox , rectum , neoadjuvant therapy , colorectal cancer , total mesorectal excision , chemotherapy , chemoradiotherapy , surgery , cancer , breast cancer

Established as an adjuvant chemotherapy, CapeOX has recently been shown to have radiosensitizer property in a phase I and II studies, with appreciable downstaging and tolerable toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research